AP2015008716A0 - Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use - Google Patents
Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of useInfo
- Publication number
- AP2015008716A0 AP2015008716A0 AP2015008716A AP2015008716A AP2015008716A0 AP 2015008716 A0 AP2015008716 A0 AP 2015008716A0 AP 2015008716 A AP2015008716 A AP 2015008716A AP 2015008716 A AP2015008716 A AP 2015008716A AP 2015008716 A0 AP2015008716 A0 AP 2015008716A0
- Authority
- AP
- ARIPO
- Prior art keywords
- oxazin
- beta
- methods
- amine compounds
- secretase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361775380P | 2013-03-08 | 2013-03-08 | |
| US201461939580P | 2014-02-13 | 2014-02-13 | |
| PCT/US2014/021412 WO2014138484A1 (fr) | 2013-03-08 | 2014-03-06 | Composés à base de 1,3-oxazin-2-amine fusionnée avec du cyclopropyle perfluoré utilisables en tant qu'inhibiteurs de la bêta-sécrétase et leurs procédés d'utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2015008716A0 true AP2015008716A0 (en) | 2015-09-30 |
Family
ID=50478936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2015008716A AP2015008716A0 (en) | 2013-03-08 | 2014-03-06 | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US9085576B2 (fr) |
| EP (1) | EP2964644B1 (fr) |
| JP (1) | JP6374889B2 (fr) |
| KR (1) | KR20150124985A (fr) |
| CN (1) | CN105164121A (fr) |
| AP (1) | AP2015008716A0 (fr) |
| AU (1) | AU2014225604B2 (fr) |
| BR (1) | BR112015021336A2 (fr) |
| CA (1) | CA2903215C (fr) |
| CL (1) | CL2015002516A1 (fr) |
| CR (1) | CR20150519A (fr) |
| EA (1) | EA201591614A1 (fr) |
| HK (1) | HK1217486A1 (fr) |
| IL (1) | IL240829A0 (fr) |
| MX (1) | MX2015011618A (fr) |
| PE (1) | PE20151794A1 (fr) |
| PH (1) | PH12015502001A1 (fr) |
| SG (1) | SG11201507196WA (fr) |
| TN (1) | TN2015000382A1 (fr) |
| TW (1) | TW201446760A (fr) |
| UY (1) | UY35377A (fr) |
| WO (1) | WO2014138484A1 (fr) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ589590A (en) | 2008-06-13 | 2012-05-25 | Shionogi & Co | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity |
| RU2012129168A (ru) † | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | Производные оксазина |
| EP2912035A4 (fr) | 2012-10-24 | 2016-06-15 | Shionogi & Co | Dérivés de dihydrooxazine ou d'oxazépine ayant une activité inhibitrice de bace1 |
| EP2961749B1 (fr) | 2013-03-01 | 2019-10-09 | Amgen Inc. | Composés perfluorés 5,6-dihydro-4h-1,3-oxazine-2-amine substitués en tant qu'inhibiteurs de la bêta-sécrétase et procédés d'utilisation correspondants |
| JP6374889B2 (ja) | 2013-03-08 | 2018-08-15 | アムジエン・インコーポレーテツド | β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合１，３−オキサジン−２−アミン化合物、及び使用方法 |
| WO2014142219A1 (fr) | 2013-03-13 | 2014-09-18 | アステラス製薬株式会社 | Composé ester d'acide guanidinobenzoïque |
| US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| CN106795147B (zh) * | 2014-08-08 | 2020-09-22 | 美国安进公司 | 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法 |
| WO2016044120A1 (fr) * | 2014-09-19 | 2016-03-24 | Merck Sharp & Dohme Corp. | Composés d'amidine à diazine fusionnée utilisés en tant qu'inhibiteurs de bace, compositions et leur utilisation |
| WO2016118404A1 (fr) * | 2015-01-20 | 2016-07-28 | Merck Sharp & Dohme Corp. | Dioxydes d'iminothiadiazine portant un substituant lié à une amine, utilisés en tant qu'inhibiteurs de bace, compositions les contenant et leur utilisation |
| US9815859B2 (en) | 2015-05-07 | 2017-11-14 | Bristol-Myers Squibb Company | Tricyclic sulfones as RORγ modulators |
| EP3331870B1 (fr) * | 2015-08-07 | 2021-06-16 | Bayer CropScience Aktiengesellschaft | Derives d'heterocyclene condenses 2-(het)aryl-substitues en tant que pesticides |
| MA52119A (fr) | 2015-10-19 | 2018-08-29 | Ncyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| EP3165093A1 (fr) | 2015-11-05 | 2017-05-10 | Basf Se | Oxadiazoles substitués pour lutter contre des fongus phytopathogènes |
| SG11201804152RA (en) | 2015-11-19 | 2018-06-28 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| TW201726623A (zh) * | 2015-12-17 | 2017-08-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| ES2844374T3 (es) * | 2015-12-22 | 2021-07-22 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| EP3452476B1 (fr) | 2016-05-06 | 2021-12-15 | Incyte Corporation | Composés hétérocycliques utilisés comme immunomodulateurs |
| TW201808902A (zh) | 2016-05-26 | 2018-03-16 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| ES2927984T3 (es) | 2016-06-20 | 2022-11-14 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2930092T3 (es) | 2016-07-14 | 2022-12-07 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| CN106432071B (zh) * | 2016-09-05 | 2019-04-02 | 河北正朗制药有限公司 | 5-氰基-4-甲氧基-2-吡啶甲酸的盐酸盐的制备及其应用 |
| WO2018071314A1 (fr) | 2016-10-10 | 2018-04-19 | Bristol-Myers Squibb Company | Sulfones tricycliques en tant que modulateurs de ror gamma |
| ES2910791T3 (es) | 2016-12-15 | 2022-05-13 | Amgen Inc | Derivados de tiazina como inhibidores de beta-secretasa y métodos de uso |
| MX2019007104A (es) | 2016-12-15 | 2019-11-05 | Amgen Inc | Derivados de dioxido de 1,4-tiazina y dioxido de 1,2,4-tiadiazina como inhibidores de beta-secretasa y metodos de uso. |
| CA3047287A1 (fr) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Derives thiazine fusionnes a un cyclopropyle utilises en tant qu'inhibiteurs de la beta-secretase et procedes d'utilisation |
| CA3047285A1 (fr) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Derives de thiazine et d'oxazine bicycliques en tant qu'inhibiteurs de beta-secretase et procedes d'utilisation |
| US10947223B2 (en) | 2016-12-15 | 2021-03-16 | Amgen Inc. | Substituted oxazines as beta-secretase inhibitors |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| MX2019007651A (es) | 2016-12-22 | 2020-02-07 | Incyte Corp | Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion de ligando 1 de muerte programada (pd-l1). |
| EP3558985B1 (fr) | 2016-12-22 | 2022-09-07 | Incyte Corporation | Dérivés de benzooxazole en tant qu'mmunomodulateurs |
| US20180179179A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MX2020010321A (es) | 2018-03-30 | 2021-01-08 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
| CA3098430A1 (fr) | 2018-04-27 | 2019-10-31 | Shionogi & Co., Ltd. | Derives de tetrahydropyranooxazine presentant une activite inhibitrice selective de bace1 |
| DK3790877T3 (da) | 2018-05-11 | 2023-04-24 | Incyte Corp | Tetrahydro-imidazo[4,5-c]pyridinderivater som pd-l1-immunmodulatorer |
| CN110759860B (zh) * | 2018-07-27 | 2022-10-14 | 江苏瑞科医药科技有限公司 | 一种3-甲酸甲酯-4-甲氧基-5-氰基吡啶的制备方法 |
| CN110183392B (zh) * | 2019-06-14 | 2023-03-28 | 河北医科大学 | 一种3-取代苯基-4，5-二氢异噁唑衍生物的制备方法及其用途和中间体 |
| EP4010342A1 (fr) | 2019-08-09 | 2022-06-15 | Incyte Corporation | Sels d'un inhibiteur de pd-1/pd-l1 |
| CA3155852A1 (fr) | 2019-09-30 | 2021-04-08 | Incyte Corporation | Composes pyrido[3,2-d]pyrimidine en tant qu'immunomodulateurs |
| MX2022005651A (es) | 2019-11-11 | 2022-07-27 | Incyte Corp | Sales y formas cristalinas de un inhibidor de la proteina de muerte celular programada 1 (pd-1)/ligando de muerte celular programada 1 (pd-l1). |
| CN113087669B (zh) * | 2019-12-23 | 2023-11-17 | 南京药石科技股份有限公司 | 一种4-氰基-5-溴嘧啶的制备方法 |
| AU2021267657A1 (en) | 2020-05-05 | 2022-12-08 | Basf Se | Condensed isoxazoline derivatives and their use as herbicides |
| WO2022099018A1 (fr) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Procédé de préparation d'un inhibiteur de pd-1/pd-l1 |
| JP2023548859A (ja) | 2020-11-06 | 2023-11-21 | インサイト・コーポレイション | Ｐｄ－１／ｐｄ－ｌ１阻害剤ならびにその塩及び結晶形態を作製するためのプロセス |
| WO2022099075A1 (fr) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Forme cristalline d'un inhibiteur pd-1/pd-l1 |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
| SI9300303A (en) | 1993-06-08 | 1994-12-31 | Krka Tovarna Zdravil | Process for isolation of hypolipemic effective substance |
| US5942400A (en) | 1995-06-07 | 1999-08-24 | Elan Pharmaceuticals, Inc. | Assays for detecting β-secretase |
| US20040234976A1 (en) | 1998-09-24 | 2004-11-25 | Gurney Mark E. | Alzheimer's disease secretase, app substrates therefor, and uses therefor |
| PT1115874E (pt) | 1998-09-24 | 2009-04-09 | Pharmacia & Upjohn Co Llc | Secretase da doença de alzheimer |
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| SG163508A1 (en) | 2003-12-15 | 2010-08-30 | Schering Corp | Heterocyclic aspartyl protease inhibitors |
| RU2416603C9 (ru) | 2005-10-25 | 2012-06-20 | Сионоги Энд Ко., Лтд. | Производные аминодигидротиазина |
| WO2008062739A1 (fr) | 2006-11-20 | 2008-05-29 | Japan Tobacco Inc. | Pyrazoles et leur utilisation en tant que médicaments |
| ES2476605T3 (es) | 2007-04-24 | 2014-07-15 | Shionogi & Co., Ltd. | Derivados de aminohidrotiazina sustituidos con grupos cíclicos |
| WO2008133273A1 (fr) | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | Composition pharmaceutique pour le traitement de la maladie d'alzheimer |
| EA015952B1 (ru) | 2007-05-03 | 2011-12-30 | Пфайзер Лимитед | 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов |
| US8158620B2 (en) | 2008-01-18 | 2012-04-17 | Eisai R&D Management Co., Ltd. | Fused aminodihydrothiazine derivatives |
| TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Ｂａｃｅ抑制劑 |
| NZ589590A (en) | 2008-06-13 | 2012-05-25 | Shionogi & Co | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity |
| WO2010013302A1 (fr) | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Dérivé de spiroaminodihydrothiazine |
| CN102105475B (zh) | 2008-07-28 | 2014-04-09 | 卫材R&D管理有限公司 | 螺氨基二氢噻嗪衍生物 |
| US8461160B2 (en) | 2009-05-08 | 2013-06-11 | Hoffmann-La Roche, Inc. | Dihydropyrimidinones |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
| US8188079B2 (en) | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
| US20110065695A1 (en) | 2009-09-11 | 2011-03-17 | Jeremy Beauchamp | Use of aminodihydrothiazines for the treatment or prevention of diabetes |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| WO2011058763A1 (fr) | 2009-11-13 | 2011-05-19 | 塩野義製薬株式会社 | Dérivé d'aminothiazine ou d'aminooxazine contenant un lieur amino |
| WO2011071057A1 (fr) | 2009-12-09 | 2011-06-16 | 塩野義製薬株式会社 | Composition pharmaceutique pour le traitement ou la prévention de la maladie d'alzheimer contenant un dérivé hétérocyclique contenant du soufre |
| EP2514747A4 (fr) | 2009-12-09 | 2013-05-08 | Shionogi & Co | Dérivé d'aminothiazine substitué |
| US7964594B1 (en) | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
| RU2012129168A (ru) * | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | Производные оксазина |
| UA103272C2 (uk) | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
| EP2511269A4 (fr) | 2009-12-11 | 2013-04-24 | Shionogi & Co | Composé hétérocyclique fusionné comportant un groupement amino |
| US8673894B2 (en) * | 2010-05-07 | 2014-03-18 | Hoffmann-La Roche Inc. | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds |
| EP2663559B1 (fr) | 2011-01-12 | 2015-07-01 | Novartis AG | Dérivés d'oxazine et leur utilisation dans le traitement de maladies neurologiques |
| CN103596569A (zh) | 2011-01-13 | 2014-02-19 | 诺瓦提斯公司 | 用于治疗代谢障碍的bace-2抑制剂 |
| US8404680B2 (en) | 2011-02-08 | 2013-03-26 | Hoffmann-La Roche Inc. | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors |
| WO2012138734A1 (fr) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | Composés de dioxyde de thiadiazine condensés avec des dérivés oxacycliques en c5-c6 comme inhibiteurs de bace, compositions, et utilisation use |
| US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
| US9499502B2 (en) | 2011-04-13 | 2016-11-22 | Merck Sharp & Dohme Corp. | 5-substituted iminothiazines and their mono- and dioxides as BACE inhibitors, compositions, and their use |
| WO2012147762A1 (fr) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | Dérivé de pyridine et inhibiteur de bace-1 le contenant |
| EP2703399A4 (fr) | 2011-04-26 | 2014-10-15 | Shionogi & Co | Dérivé d'oxazine et inhibiteur de bace 1 le contenant |
| US8785436B2 (en) | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
| US8604024B2 (en) | 2011-05-24 | 2013-12-10 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| AR086539A1 (es) | 2011-05-24 | 2014-01-08 | Bristol Myers Squibb Co | COMPUESTOS PARA LA REDUCCION DE LA PRODUCCION DE b-AMILOIDE |
| US9079919B2 (en) | 2011-05-27 | 2015-07-14 | Hoffmann-La Roche Inc. | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors |
| AR086653A1 (es) | 2011-06-03 | 2014-01-15 | Bristol Myers Squibb Co | COMPUESTOS PARA LA REDUCCION DE PRODUCCION DE b-AMILOIDE |
| JP2012250933A (ja) | 2011-06-03 | 2012-12-20 | Shionogi & Co Ltd | オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物 |
| CA2837797A1 (fr) | 2011-06-07 | 2012-12-13 | F. Hoffmann-La Roche Ag | [1,3]oxazines |
| PE20140623A1 (es) | 2011-06-07 | 2014-05-30 | Hoffmann La Roche | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 |
| US8927535B2 (en) * | 2011-07-06 | 2015-01-06 | Hoffman-La Roche Inc. | Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors |
| EP2747769B1 (fr) | 2011-08-22 | 2017-08-02 | Merck Sharp & Dohme Corp. | Iminothiazines 2-spiro-substituées et leur mono- et dioxydes en tant qu'inhibiteurs bace, compositions et leur utilisation |
| UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
| JP6043355B2 (ja) | 2011-08-31 | 2016-12-14 | ファイザー・インク | ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| US20130073953A1 (en) | 2011-09-21 | 2013-03-21 | Timothy Onyenobi | News headline screenshot viewing system |
| CN103987710A (zh) | 2011-10-13 | 2014-08-13 | 诺华股份有限公司 | 新的*嗪衍生物及它们在治疗疾病中的应用 |
| JPWO2013061962A1 (ja) | 2011-10-24 | 2015-04-02 | 武田薬品工業株式会社 | 二環性化合物 |
| NZ625684A (en) | 2012-01-26 | 2016-02-26 | Hoffmann La Roche | Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines |
| CA2867851A1 (fr) | 2012-03-20 | 2013-09-26 | Elan Pharmaceuticals, Inc. | Dihydro-thiazine spirocycliques et inhibiteurs de bace dihydro-oxazine et compositions et utilisations de ceux-ci |
| EP2852597B1 (fr) | 2012-05-04 | 2016-06-08 | Pfizer Inc | Composés d'hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par des hétérocycliques à titre d'inhibiteurs d'app, bace1 et bace2 |
| WO2013182638A1 (fr) | 2012-06-08 | 2013-12-12 | H. Lundbeck A/S | 2-aminothiazinylhétéroaryles en tant qu'inhibiteurs de bace1 pour le traitement de la maladie d'alzheimer |
| MA37763B1 (fr) | 2012-06-26 | 2017-05-31 | Hoffmann La Roche | Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 |
| GB201212871D0 (en) | 2012-07-20 | 2012-09-05 | Eisai Ltd | Novel compounds |
| CA2882389A1 (fr) | 2012-09-20 | 2014-03-27 | Pfizer Inc. | Composes d'hexahydropyrano[3,4-d][1,3]thiazine-2-amine alkyl-substitues |
| WO2014059185A1 (fr) | 2012-10-12 | 2014-04-17 | Amgen Inc. | Composés amino-dihydrothiazine et amino-dioxydo dihydrothiazine en tant qu'antagonistes de bêta-sécrétase et procédés d'utilisation |
| WO2014062549A1 (fr) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | Composés de dioxyde de thiadiazine substitués tricycliques en tant qu'inhibiteurs de bace, compositions et leur utilisation |
| WO2014062553A1 (fr) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | Composés de dioxyde de thiadiazine substituée tricyclique utilisés en tant qu'inhibiteurs de bace, compositions et leur utilisation |
| EP2912035A4 (fr) | 2012-10-24 | 2016-06-15 | Shionogi & Co | Dérivés de dihydrooxazine ou d'oxazépine ayant une activité inhibitrice de bace1 |
| WO2014066132A1 (fr) | 2012-10-26 | 2014-05-01 | Eli Lilly And Company | Inhibiteurs de bace |
| WO2014093190A1 (fr) | 2012-12-14 | 2014-06-19 | Merck Sharp & Dohme Corp. | Dioxydes d'iminothiadiazine en tant qu'inhibiteurs de bace |
| EP2935282A1 (fr) | 2012-12-19 | 2015-10-28 | Pfizer Inc. | Composés hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués carbocycliques et hétérocycliques |
| US9475784B2 (en) | 2012-12-19 | 2016-10-25 | Bristol-Myers Squibb Company | 4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production |
| CA2894919A1 (fr) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Composes de dioxyde d'iminothiazine a condensation oxacyclique en c5, c6 comme inhibiteurs de bace |
| WO2014099788A1 (fr) | 2012-12-21 | 2014-06-26 | Merck Sharp & Dohme Corp. | Dioxydes d'iminothiadiazine spiro c5 utilisés en tant qu'inhibiteurs de bace |
| JP2016505055A (ja) | 2013-01-22 | 2016-02-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂａｃｅ１阻害剤としてのフルオロ−［１，３］オキサジン |
| EP2961749B1 (fr) | 2013-03-01 | 2019-10-09 | Amgen Inc. | Composés perfluorés 5,6-dihydro-4h-1,3-oxazine-2-amine substitués en tant qu'inhibiteurs de la bêta-sécrétase et procédés d'utilisation correspondants |
| JP6374889B2 (ja) * | 2013-03-08 | 2018-08-15 | アムジエン・インコーポレーテツド | β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合１，３−オキサジン−２−アミン化合物、及び使用方法 |
| KR20150131241A (ko) | 2013-03-15 | 2015-11-24 | 브라이엄 영 유니버시티 | 스트레인 게이지로서 사용되는 복합 재료 |
| US11447478B2 (en) | 2013-04-11 | 2022-09-20 | Hoffmann-La Roche Inc. | BACE1 inhibitors |
| JP2016517858A (ja) | 2013-04-26 | 2016-06-20 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂａｃｅインヒビターの合成 |
| TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物 |
| CN106795147B (zh) | 2014-08-08 | 2020-09-22 | 美国安进公司 | 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法 |
-
2014
- 2014-03-06 JP JP2015561682A patent/JP6374889B2/ja active Active
- 2014-03-06 EP EP14717004.7A patent/EP2964644B1/fr active Active
- 2014-03-06 SG SG11201507196WA patent/SG11201507196WA/en unknown
- 2014-03-06 KR KR1020157026887A patent/KR20150124985A/ko not_active Application Discontinuation
- 2014-03-06 PE PE2015001879A patent/PE20151794A1/es not_active Application Discontinuation
- 2014-03-06 AP AP2015008716A patent/AP2015008716A0/xx unknown
- 2014-03-06 MX MX2015011618A patent/MX2015011618A/es active IP Right Grant
- 2014-03-06 US US14/199,844 patent/US9085576B2/en active Active
- 2014-03-06 CA CA2903215A patent/CA2903215C/fr active Active
- 2014-03-06 WO PCT/US2014/021412 patent/WO2014138484A1/fr active Application Filing
- 2014-03-06 BR BR112015021336A patent/BR112015021336A2/pt not_active IP Right Cessation
- 2014-03-06 CN CN201480013095.9A patent/CN105164121A/zh active Pending
- 2014-03-06 EA EA201591614A patent/EA201591614A1/ru unknown
- 2014-03-06 AU AU2014225604A patent/AU2014225604B2/en active Active
- 2014-03-07 TW TW103108045A patent/TW201446760A/zh unknown
- 2014-03-10 UY UY0001035377A patent/UY35377A/es not_active Application Discontinuation
-
2015
- 2015-04-21 US US14/691,715 patent/US20150252011A1/en not_active Abandoned
- 2015-08-25 IL IL240829A patent/IL240829A0/en unknown
- 2015-08-31 TN TN2015000382A patent/TN2015000382A1/en unknown
- 2015-09-08 PH PH12015502001A patent/PH12015502001A1/en unknown
- 2015-09-08 CL CL2015002516A patent/CL2015002516A1/es unknown
- 2015-10-05 CR CR20150519A patent/CR20150519A/es unknown
- 2015-11-04 US US14/932,787 patent/US9611261B2/en active Active
-
2016
- 2016-05-12 HK HK16105452.2A patent/HK1217486A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2903215C (fr) | 2021-07-20 |
| UY35377A (es) | 2014-09-30 |
| JP6374889B2 (ja) | 2018-08-15 |
| PH12015502001A1 (en) | 2016-01-11 |
| TW201446760A (zh) | 2014-12-16 |
| CL2015002516A1 (es) | 2016-03-28 |
| JP2016510758A (ja) | 2016-04-11 |
| EP2964644A1 (fr) | 2016-01-13 |
| US20140275058A1 (en) | 2014-09-18 |
| PE20151794A1 (es) | 2015-12-03 |
| US9611261B2 (en) | 2017-04-04 |
| CN105164121A (zh) | 2015-12-16 |
| US9085576B2 (en) | 2015-07-21 |
| EP2964644B1 (fr) | 2018-12-26 |
| US20160280695A1 (en) | 2016-09-29 |
| AU2014225604A1 (en) | 2015-09-10 |
| IL240829A0 (en) | 2015-10-29 |
| MX2015011618A (es) | 2015-12-17 |
| EA201591614A1 (ru) | 2015-12-30 |
| US20150252011A1 (en) | 2015-09-10 |
| AU2014225604B2 (en) | 2018-05-17 |
| CR20150519A (es) | 2016-01-11 |
| SG11201507196WA (en) | 2015-10-29 |
| CA2903215A1 (fr) | 2014-09-12 |
| WO2014138484A1 (fr) | 2014-09-12 |
| KR20150124985A (ko) | 2015-11-06 |
| TN2015000382A1 (en) | 2017-01-03 |
| HK1217486A1 (zh) | 2017-01-13 |
| BR112015021336A2 (pt) | 2017-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1217486A1 (zh) | 作爲β-分泌酶抑制劑的全氟化環丙基稠合的 -噁嗪- -胺化合物以及其使用方法 | |
| HRP20170888T1 (hr) | Spoj tubulisina, metode pripreme i primjena | |
| HK1223913A1 (zh) | 經取代的苯甲酰胺及其使用方法 | |
| IL245184B (en) | Prostacyclin compounds, preparations and methods of using them | |
| IL246252A0 (en) | Diaminopyrimidyl derivative compounds, their compositions and methods of treatment | |
| IL244268A0 (en) | Heterocyclic compounds and methods of use | |
| EP3083589A4 (fr) | Composés pipéraziniques substitués et leurs procédés d'utilisation | |
| PT3019477T (pt) | Compostos heterocíclicos e métodos para a sua utilização | |
| EP2971065A4 (fr) | Composés de sonde basée sur l'activité, compositions et méthodes d'utilisation | |
| IL244066A0 (en) | Triazolopyridine compounds, preparations and methods for their use | |
| PT2967044T (pt) | Composição herbicida e seu método de uso | |
| HK1218254A1 (zh) | 用拉喹莫德治療多發性硬化症 | |
| PL3055679T3 (pl) | Środek do wykrywania pęknięć, sposób jego wytwarzania i zastosowanie środka do wykrywania pęknięć | |
| EP2967055A4 (fr) | Compositions biocides, procédés de fabrication et procédés d'utilisation | |
| EP2947815A4 (fr) | Procédé pour découvrir un utilisateur d'équipement, et équipement d'utilisateur | |
| GB201303476D0 (en) | Agrochemical composition and method of use thereof | |
| GB2525530B (en) | Treatment of hard surfaces | |
| GB201310349D0 (en) | Composition and method of use thereof | |
| GB201301928D0 (en) | Composition and method of use thereof |